These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15223190)

  • 21. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.
    Woodward ND; Purdon SE; Meltzer HY; Zald DH
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):457-72. PubMed ID: 15784157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC; Crawford AM
    J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
    Smith RC; Lindenmayer JP; Davis JM; Cornwell J; Noth K; Gupta S; Sershen H; Lajtha A
    Schizophr Res; 2009 May; 110(1-3):149-55. PubMed ID: 19251401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].
    Radziwiłłowicz P; Radziwiłłowicz W; Lis J
    Psychiatr Pol; 2002; 36(6):967-87. PubMed ID: 12725025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.
    Takahashi H; Yoshida K; Ishigooka J; Higuchi H
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1067-72. PubMed ID: 16759777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic drug effects on brain morphology in first-episode psychosis.
    Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
    Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia.
    Sumiyoshi C; Sumiyoshi T; Roy A; Jayathilake K; Meltzer HY
    Int J Neuropsychopharmacol; 2006 Dec; 9(6):677-83. PubMed ID: 16313705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression.
    Hill SK; Keshavan MS; Thase ME; Sweeney JA
    Am J Psychiatry; 2004 Jun; 161(6):996-1003. PubMed ID: 15169687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.
    Bertolino A; Caforio G; Blasi G; De Candia M; Latorre V; Petruzzella V; Altamura M; Nappi G; Papa S; Callicott JH; Mattay VS; Bellomo A; Scarabino T; Weinberger DR; Nardini M
    Am J Psychiatry; 2004 Oct; 161(10):1798-805. PubMed ID: 15465976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of olanzapine on cognitive functions in patients with schizophrenia during an observation period of six months.
    Klasik A; Krysta K; Krzystanek M; Skałacka K
    Psychiatr Danub; 2011 Sep; 23 Suppl 1():S83-6. PubMed ID: 21894109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia.
    Hori H; Yoshimura R; Katsuki A; Atake K
    Int Clin Psychopharmacol; 2020 Mar; 35(2):89-97. PubMed ID: 31743230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine.
    Littrell KH; Petty RG; Hilligoss NM; Kirshner CD; Johnson CG
    Schizophr Res; 2004 Feb; 66(2-3):201-2. PubMed ID: 15061258
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.